These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 10064661)
21. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920 [TBL] [Abstract][Full Text] [Related]
23. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Bronsky EA; Kemp JP; Zhang J; Guerreiro D; Reiss TF Clin Pharmacol Ther; 1997 Nov; 62(5):556-61. PubMed ID: 9390112 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. Manning PJ; Watson RM; Margolskee DJ; Williams VC; Schwartz JI; O'Byrne PM N Engl J Med; 1990 Dec; 323(25):1736-9. PubMed ID: 2174121 [TBL] [Abstract][Full Text] [Related]
25. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708 [TBL] [Abstract][Full Text] [Related]
26. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Peroni DG; Piacentini GL; Ress M; Bodini A; Loiacono A; Aralla R; Boner AL Pediatr Allergy Immunol; 2002 Dec; 13(6):434-7. PubMed ID: 12485319 [TBL] [Abstract][Full Text] [Related]
27. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152 [TBL] [Abstract][Full Text] [Related]
28. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Lehnigk B; Rabe KF; Dent G; Herst RS; Carpentier PJ; Magnussen H Eur Respir J; 1998 Mar; 11(3):617-23. PubMed ID: 9596112 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L Respiration; 2001; 68(5):452-9. PubMed ID: 11694805 [TBL] [Abstract][Full Text] [Related]
30. Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Westbroek J; Pasma HR Respir Med; 2000 Feb; 94(2):112-8. PubMed ID: 10714415 [TBL] [Abstract][Full Text] [Related]
31. [Single dose of montelukast as an effective prevention of post exercise bronchospasm in children with bronchial asthma]. Gaszczyk G; Latoś T; Słowikowski A; Janiak B Med Wieku Rozwoj; 2004; 8(3 Pt 2):847-56. PubMed ID: 15858257 [TBL] [Abstract][Full Text] [Related]
32. The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction. Schelfhout V; Van De Velde V; Pauwels R; Joos G Pulm Pharmacol Ther; 2008; 21(2):276-84. PubMed ID: 17611132 [TBL] [Abstract][Full Text] [Related]
33. Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast. Wasfi YS; Kemp JP; Villarán C; Massaad R; Xin W; Smugar SS; Knorr BA; Philip G Allergy Asthma Proc; 2011; 32(6):453-9. PubMed ID: 22221440 [TBL] [Abstract][Full Text] [Related]
34. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pajaron-Fernandez M; Garcia-Rubia S; Sanchez-Solis M; Garcia-Marcos L Pediatr Pulmonol; 2006 Mar; 41(3):222-7. PubMed ID: 16429427 [TBL] [Abstract][Full Text] [Related]
35. Summary of clinical trials with zafirlukast. Calhoun WJ Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S238-45; discussion S245-8. PubMed ID: 9647606 [TBL] [Abstract][Full Text] [Related]
36. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Finnerty JP; Wood-Baker R; Thomson H; Holgate ST Am Rev Respir Dis; 1992 Apr; 145(4 Pt 1):746-9. PubMed ID: 1554195 [TBL] [Abstract][Full Text] [Related]
37. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. Tashkin DP; Nathan RA; Howland WC; Minkwitz MC; Simonson SG; Bonuccelli CM J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):246-54. PubMed ID: 9949315 [TBL] [Abstract][Full Text] [Related]
38. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Peroni DG; Pescollderungg L; Sandri M; Chinellato I; Boner AL; Piacentini GL Respir Med; 2011 Dec; 105(12):1790-7. PubMed ID: 21865022 [TBL] [Abstract][Full Text] [Related]
39. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Vidal C; Fernández-Ovide E; Piñeiro J; Nuñez R; González-Quintela A Ann Allergy Asthma Immunol; 2001 Jun; 86(6):655-8. PubMed ID: 11428738 [TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. Grossman J; Smith LJ; Wilson AM; Thyrum PT Ann Allergy Asthma Immunol; 1999 Apr; 82(4):361-9. PubMed ID: 10227334 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]